Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 196-201 , 1 March 2010

Adolescent cannabis use increases risk for cocaine-induced paranoia

  • Rasmon Kalayasiri

      Affiliations

    • Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
    • ,
  • Joel Gelernter

      Affiliations

    • Department of Psychiatry, Yale School of Medicine, New Haven, CT 06520, USA
    • ,
  • Lindsay Farrer

      Affiliations

    • Departments of Medicine (Genetics Program) and Neurology and Genetics, Boston University School of Medicine, and Departments of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA 02218, USA
    • ,
  • Roger Weiss

      Affiliations

    • Department of Psychiatry, Harvard Medical School, Boston, MA 02215, USA
    • Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA 02478, USA
    • ,
  • Kathleen Brady

      Affiliations

    • Department of Psychiatry, Medical University of South Carolina, Charleston, SC 29425, USA
    • ,
  • Ralitza Gueorguieva

      Affiliations

    • School of Public Health, Yale School of Medicine, New Haven, CT 06520, USA
    • ,
  • Henry R. Kranzler

      Affiliations

    • Departments of Psychiatry and Genetics and Developmental Biology, University of Connecticut School of Medicine, Farmington, CT 06030, USA
    • ,
  • Robert T. Malison

      Affiliations

    • Department of Psychiatry, Yale School of Medicine, New Haven, CT 06520, USA
    • Corresponding Author InformationCorresponding author at: Clinical Neuroscience Research Unit, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA. Tel.: +1 203 974 7557; fax: +1 203 974 7662.

Received 3 June 2009 ,Revised 13 October 2009 ,Accepted 21 October 2009.

References 

  1. Addiction Research Center (NIDA) Clinical manifestations of addiction, Baltimore.
  2. Agrawal A, Neale MC, Prescott CA, Kendler KS . A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol. Med. 2004;34:1227–1237
  3. Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, et al. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome. Am. J. Drug Alcohol Abuse. 2006;32:629–635
  4. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry. 2004;184:110–117
  5. Bartlett E, Hallin A, Chapman B, Angrist B. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability?. Neuropsychopharmacology. 1997;16:77–82
  6. Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry. 2002;52:701–707
  7. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J. Clin. Psychiatry. 1991;52:509–512
  8. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry. 2005;57:1117–1127
  9. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry. 2001;50:71–83
  10. Cubells JF, Feinn R, Pearson D, Burda J, Tang Y, Farrer LA, et al. Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP). Drug Alcohol Depend. 2005;80:23–33
  11. Cubells JF, Kranzler HR, McCance-Katz E, Anderson GM, Malison RT, Price LH, et al. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol. Psychiatry. 2000;5:56–63
  12. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis?. Can. J. Psychiatry. 2006;51:556–565
  13. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry. 2005;57:594–608
  14. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2008;198:587–603
  15. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572
  16. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2001;98:6917–6922
  17. Fan JB, Zhang CS, Gu NF, Li XW, Sun WW, Wang HY, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol. Psychiatry. 2005;57:139–144
  18. Farrer LA, Kranzler HR, Yu Y, Weiss RD, Brady KT, Anton R, et al. Association of variants in MANEA with cocaine-related behaviors. Arch. Gen. Psychiatry. 2009;66:267–274
  19. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 2006;101:556–569
  20. Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use?. Addiction. 2000;95:505–520
  21. Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ. 2006;332:172–175
  22. Floyd AG, Boutros NN, Struve FA, Wolf E, Oliwa GM. Risk factors for experiencing psychosis during cocaine use: a preliminary report. J. Psychiatr. Res. 2006;40:178–182
  23. Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology. 1994;11:195–200
  24. Gelernter J, Panhuysen C, Weiss R, Brady K, Hesselbrock V, Rounsaville B, et al. Genomewide linkage scan for cocaine dependence and related traits: significant linkages for a cocaine-related trait and cocaine-induced paranoia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005;136B:45–52
  25. Gelernter J, Panhuysen C, Wilcox M, Hesselbrock V, Rounsaville B, Poling J, et al. Genomewide linkage scan for opioid dependence and related traits. Am. J. Hum. Genet. 2006;78:759–769
  26. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case–control and family-based studies. Am. J. Psychiatry. 2003;160:469–476
  27. Hall W. Is cannabis use psychotogenic?. Lancet. 2006;367:193–195
  28. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31:2748–2757
  29. Kalayasiri R, Kranzler HR, Weiss R, Brady K, Gueorguieva R, Panhuysen C, et al. Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug Alcohol Depend. 2006;84:77–84
  30. Kalayasiri R, Sughondhabirom A, Gueorguieva R, Coric V, Lynch WJ, Lappalainen J, et al. Dopamine beta-hydroxylase gene (DbetaH) −1021C→T influences self-reported paranoia during cocaine self-administration. Biol. Psychiatry. 2007;61:1310–1313
  31. Kalayasiri R, Sughondhabirom A, Gueorguieva R, Coric V, Lynch WJ, Morgan PT, et al. Self-reported paranoia during laboratory “binge” cocaine self-administration in humans. Pharmacol. Biochem. Behav. 2006;83:249–256
  32. Kandel D. Stages in adolescent involvement in drug use. Science. 1975;190:912–914
  33. Kandel DB, Yamaguchi K, Klein LC. Testing the gateway hypothesis. Addiction. 2006;101:470–472(Discussion 474–476)
  34. Linszen D, van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr. Opin. Psychiatry. 2007;20:116–120
  35. Miller NS, Klahr AL, Gold MS, Sweeney K, Cocores JA. The prevalence of marijuana (cannabis) use and dependence in cocaine dependence. N Y State J. Med. 1990;90:491–492
  36. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol. Psychiatry. 2005;10:765–770
  37. Muntaner C, Kumor KM, Nagoshi C, Jaffe JH. Intravenous cocaine infusions in humans: dose responsivity and correlations of cardiovascular vs. subjective effects. Pharmacol. Biochem. Behav. 1989;34:697–703
  38. Okochi T, Ikeda M, Kishi T, Kawashima K, Kinoshita Y, Kitajima T, et al. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr. Res. 2009;110:140–148
  39. Pierucci-Lagha A, Gelernter J, Chan G, Arias A, Cubells JF, Farrer L, et al. Reliability of DSM-IV diagnostic criteria using the semi-structured assessment for drug dependence and alcoholism (SSADDA). Drug Alcohol Depend. 2007;91:85–90
  40. Pierucci-Lagha A, Gelernter J, Feinn R, Cubells JF, Pearson D, Pollastri A, et al. Diagnostic reliability of the Semi-structured Assessment for Drug Dependence and Alcoholism (SSADDA). Drug Alcohol Depend. 2005;80:303–312
  41. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945–959
  42. Rosse RB, Fay-McCarthy M, Collins JP, Alim TN, Deutsch SI. The relationship between cocaine-induced paranoia and compulsive foraging: a preliminary report. Addiction. 1994;89:1097–1104
  43. Satel SL, Southwick SM, Gawin FH. Clinical features of cocaine-induced paranoia. Am. J. Psychiatry. 1991;148:495–498
  44. Sherer MA, Kumor KM, Cone EJ, Jaffe JH. Suspiciousness induced by four-hour intravenous infusions of cocaine. Preliminary findings. Arch. Gen. Psychiatry. 1988;45:673–677
  45. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 2002;71:1296–1302
  46. Substance Abuse and Mental Health Services Administration, 2008. Results from the 2007 National Survey on Drug Use and Health: National Findings, Office of Applied Studies, Rockville, MD.
  47. Sughondhabirom A, Jain D, Gueorguieva R, Coric V, Berman R, Lynch WJ, et al. A paradigm to investigate the self-regulation of cocaine administration in humans. Psychopharmacology (Berl). 2005;180:436–446
  48. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276:2048–2050
  49. Wonodi I, Stine OC, Mitchell BD, Buchanan RW, Thaker GK. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003;120B:47–50
  50. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O’Donovan MC, et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry. 2007;191:402–407

PII: S0376-8716(09)00396-2

doi: 10.1016/j.drugalcdep.2009.10.006

Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 196-201 , 1 March 2010

Article Tools